Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Human Metabolome Technologies Inc. (6090:JPX), powered by AI.
Human Metabolome Technologies Inc. is currently trading at ¥611. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Human Metabolome Technologies Inc. on Alpha Lenz.
Human Metabolome Technologies Inc.'s P/E ratio is 14.0.
“Human Metabolome Technologies Inc. trades at a P/E of 14.0 (undervalued) with solid ROE of 13.3%.”
Ask for details →Human Metabolome Technologies Inc. is an innovative entity within the biotechnology sector, focused on providing comprehensive metabolomics services and products. The company's primary function is to analyze and quantify small molecules known as metabolites within biological samples. Their cutting-edge technology plays a crucial role in supporting drug discovery, diagnostics development, and therapeutic research. Human Metabolome Technologies Inc. addresses various industries, including pharmaceuticals, healthcare, and academic research. By leveraging advanced analytical methods, the company enables clients to gain insights into metabolic functions and pathways, ultimately enhancing understanding of diseases and biological processes. Established with a vision to pioneer metabolic profiling, Human Metabolome Technologies Inc. continues to be a significant contributor to advancements in life sciences and personalized medicine.
“Human Metabolome Technologies Inc. trades at a P/E of 14.0 (undervalued) with solid ROE of 13.3%.”
Ask for details →Human Metabolome Technologies Inc. (ticker: 6090) is a company listed on JPX in the Healthcare sector (Diagnostics & Research). It has approximately 62 employees. Market cap is $3.6B.
The current price is 611 with a P/E ratio of 13.99x and P/B of 1.88x.
ROE is 13.30% and operating margin is 17.15%. Annual revenue is $1.5B.